Why high good cholesterol can be bad news

first_imgThe 67-year-old woman had sky-high high-density lipoprotein (HDL), the form of cholesterol long seen as protective against heart disease, and yet her arteries were lined with plaque. Her paradoxical case has helped motivate a team of scientists to show how high HDL can sometimes be a signal not of heart health, but of the opposite: a cholesterol system unable to siphon the fatty particles from circulation.In the last 10 years, HDL particles have confounded scientists. The normal role of these bundles of protein and fat is to ferry cholesterol from the rest of the body to the liver, which eliminates it from the body. More of something good should mean better health, and people who naturally have higher HDL levels are usually better off. But drugs that increase HDL cholesterol have flopped in clinical trials, and genes that help raise it don’t seem to track with less heart disease. “Nothing with HDL’s ever simple,” says Jay Heinecke, a biochemist at the University of Washington, Seattle, who has studied it for years.In this week’s issue of Science, Daniel Rader, a geneticist and lipidologist at the University of Pennsylvania, and his colleagues suggest that the amount of HDL is less important than how efficiently it gets moved from arteries into the liver. Rader’s inspiration was a mouse model developed by Monty Krieger at the Massachusetts Institute of Technology in Cambridge about 
20 years ago. The mouse’s developers had deleted a gene called SCARB1, resulting in animals with startlingly high HDL and, just as startlingly, severely clogged arteries. “Mice actually get heart attacks,” Heinecke says. That’s because the system for moving cholesterol out of the body is broken in these mice. Normally, HDL particles gather cholesterol from immune cells that line the arteries, and then deposit their load in the liver so that the cycle can begin again. The protein made by the SCARB1 gene, known as SR-B1, helps make that deposit happen. Mice without SR-B1 have HDL particles swollen with cholesterol, which struggle to draw more of it away from the arterial wall.Rader wondered whether the same thing might be happening in some people. He and his colleagues began by sequencing genes in 852 people with very high HDL and more than 1000 controls. They found one person—the 67-year-old woman—who had no functioning copies of the SCARB1 gene and had more plaque on her arteries than an average woman her age. Her HDL was 152 mg/dl, well above the average of about 62 mg/dl among women in her age group. Eighteen others had just one functional copy of SCARB1 instead of the usual two, and most of them also had high HDL. Detailed studies of nine people with SCARB1 mutations, including the woman, suggested that as in the mice, their abundant HDL failed to transport cholesterol effectively through the body.Rader then reached out to colleagues who had collected DNA on hundreds of thousands of people for studies of lipids and heart disease. Among them, he found another 284 people who had only one functioning copy of SCARB1. (No one else was like that first woman, with both copies missing.) Most of these people also had higher than average HDL. These people were also about 80% more likely than controls to have coronary artery disease—about the same increase in risk seen with traditional risk factors like diabetes and hypertension.“This is a key indication of what people have suspected from animal studies,” says Alan Tall, an HDL researcher at Columbia University. It appears that HDL is higher “because the flux is blocked,” not because HDL is excelling at keeping cholesterol out of the arteries.Still, because Rader could find so few people without fully functioning SCARB-1, and because the potential effects of the mutations on heart health appeared fairly modest, the link between faulty HDL transport and cardiac troubles is still tenuous, he and others say. And HDL’s behavior in a petri dish doesn’t necessarily reflect what it’s doing inside the body, suggests Jan Albert Kuivenhoven, who studies the genetics of lipid metabolism at the University Medical Center Groningen in the Netherlands. “We have no good ways to do the tests with HDL that can really tell what’s happening” in a person, Kuivenhoven says.HDL remains extraordinarily complex, Rader and Kuivenhoven say. It’s possible that HDL-raising drugs failed in clinical trials because of the type of HDL the drugs produced—doctors detected more large HDL particles than expected. Overall, however, there’s little question that high HDL still tracks with a healthier heart for most people—except, Rader says, when it doesn’t.Ultimately, he says, we’d like to be able to say, “Your HDL is high because X, and that’s good thing,” and in someone else, “Your HDL is high because of Y, and that’s a bad thing.” Now, he and others want to nail down exactly what those factors might be—and, potentially, how to head them off. Sign up for our daily newsletter Get more great content like this delivered right to you! Country Emailcenter_img Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Click to view the privacy policy. Required fields are indicated by an asterisk (*)last_img read more